Quiénes somos

Compañía

FibroStatin SL fue constituida en 2005. La sede de la compañía está ubicada en el Parque Científico de la Universidad de Valencia (España). Las instalaciones tienen 300 m2 de laboratorios y oficinas administrativas. Las actividades principales, incluyendo bioquímica de proteínas, biología molecular y celular, química orgánica, histología y espectrometría de masas, son realizadas en sus instalaciones por el personal científico de FibroStatin, mientras que otras actividades de investigación como ensayos pre-clínicos con animales, RMN, radioisótopos, microscopía electrónica y confocal, y resonancia de plasmones superficiales, son subcontratadas a laboratorios externos. FibroStatin SL ha establecido recientemente una filial en EE.UU, FibroStatin INC, participada al 100% por la propia Compañía, que llevará a cabo el desarrollo de negocio y el desarrollo clínico regulatorio de los compuestos de la Compañía así como su financiación. FibroStatin tiene planificado el desarrollo clínico de su candidato a fármaco en colaboración con otras empresas del sector.

Equipo Ejecutivo

Juan Saus,
M.D., Ph.D.
Founder and Scientific Director of FibroStatin SL.
Juan Saus,
M.D., Ph.D.
Founder and Scientific Director of FibroStatin SL.
Associate Professor University of Valencia; Post-doc at the Robert Wood Johnson Medical School; Post-doc at Kansas University Medical Center. Dr. Saus has 37 peer-reviewed publications in referenced international journals, 3 book chapters, 10 international utility patent applications (PCT), and 29 issued patents.
Francisco Revert,
Ph.D.
Founder and Head of Molecular Biology and Biochemistry of FibroStatin SL.
Francisco Revert,
Ph.D.
Founder and Head of Molecular Biology and Biochemistry of FibroStatin SL.
Biological Sciences degree and Pharmacy PhD at University of Valencia; Post-Doc at Príncipe Felipe Research Center. Dr. Revert-Ros has over 18 years of experience in molecular basis of human disease, 9 peer-reviewed publications in referenced international journals, 5 international utility patent applications (PCT) and 5 Granted patents.
Fernando Revert,
Ph.D.
Founder and Head of Cell Biology and Member of FibroStatin SL BOD.
Fernando Revert,
Ph.D.
Founder and Head of Cell Biology and Member of FibroStatin SL BOD.
Pharmacy PhD at University of Valencia; Post-Doc at Principe Felipe Research Center. Dr. Revert-Ros has over 23 years of experience in molecular basis of human disease, 14 peer-reviewed publications in referenced international journals, 2 book chapters, 5 international utility patent applications (PCT) and 4 Granted patents.
Luis Castillo,
B.S.
General Manager and Member of FibroStatin SL BOD
Luis Castillo,
B.S.
General Manager and Member of FibroStatin SL BOD
Industrial Engineer and Engineering Advanced Studies degree at the Polytechnic University of Valencia. Experience 15+ years in R&D management. Project Manager at IBV and ITENE, Co-Founder of Spin-Off Manager SL, Head of Department at GVA-Spain government, General Manager at Celartia LTD.
J. Wesley Fox III,
Ph.D.
President and Chief Executive Officer of FibroStatin Inc and Member of the FibroStatin SL BOD.
J. Wesley Fox III,
Ph.D.
President and Chief Executive Officer of FibroStatin Inc and Member of the FibroStatin SL BOD.
Experience 25+ years. FibroStatin SL BOD; Co-Founder of NephroGenex, BioStratum, EnzyMed (acquired by Albany Molecular Research) and RiboGene (acquired by Questcore Pharmaceuticals). R&D positions with Abbott Laboratories and Baxter Healthcare.
J. Wesley Fox IV
J.D., RAC
Director of Business Development and Regulatory Affairs
J. Wesley Fox IV
J.D., RAC
Director of Business Development and Regulatory Affairs
RAC certified regulatory affairs consultant working with developmental stage pharmaceutical companies. FDA accelerated approval; Special Protocol Assessment (SPA); FDA?s Citizen Petition policy; FDA regulation of dietary supplements.

Comité Científico Asesor

Billy G Hudson,
M.D.
Director, Center of Matrix Biology, Vanderbilt University Medical Center. Elliott V. Newman Professor, Medicine. University of Vanderbilt, TN USA.
Jörgen Wieslander,
Ph.D.
Independent Scientific Advisor, Sweden.
Charles Swanton
M.D., Ph.D.
Professor and Chair of Personalized Cancer Medicine, University College London Cancer Institute, The Francis Crick Institute, London.
Mariano Barbacid,
Ph.D.
Professor and Leader of Experimental Oncology Group, Spanish National Cancer Research Center, Madrid, Spain.
Jorge Moscat,
Ph.D.
Professor of Cancer Metabolism and Signaling Program, Sanford-Burnham Medical Research Institute, La Jolla, CA USA.
James DeGregori,
Ph.D.
Professor, Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine Denver, CO USA.

Colaboraciones

Silanes
University of Valencia
Center for Matrix Biology
Boehringer Ingelheim
University of Cantabria
Fundacion investigacion hospital general universitario valencia
Hospital universitario La Paz
Hospital quiron salud
Fundacion Marques de Valdecilla
Fundación investigación biomédica hospital 12 de octubre